Chronic Cough

Chronic cough remains a complex and often refractory clinical entity, with heterogeneous underlying mechanisms and significant impact on patient quality of life. The British Thoracic Society clinical statement on chronic cough in adults provides an updated, structured framework for assessment and management, with an emphasis on treatable traits and the recognition of cough hypersensitivity as a central pathophysiological mechanism. In this Q&A, Dr Paul Marsden (Wythenshawe Hospital, Manchester) outlines practical approaches to implementing the latest BTS recommendations in routine care, including diagnostic assessment, use of a treatable traits framework, indications for referral, and strategies for managing refractory chronic cough.

As touchRESPIRATORY approaches 10 years of providing education for busy respiratory specialists, we are looking to the future—and it certainly looks bright!

Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.

What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.

In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.

As 2024 draws to a close, we’re celebrating a fantastic year of content.

The International Primary Care Respiratory Group (IPCRG), is proud to host the 8th IPCRG Scientific Meeting in Brașov, Romania, on Friday 11 and Saturday 12 April 2025. This event, in partnership with the RespiRO team and the Transilvania University of Brașov promises to bring together researchers, innovators, and industry leaders to advance respiratory care in primary health settings.

COUGH 1 and COUGH 2, were randomized, double-blind, placebo-controlled phase 3 trials, that investigated gefapixant for the treatment of refractory or unexplained chronic cough. It was a pleasure to speak with Dr. Imran Satia (McMaster University, Hamilton, ON, Canada) around his analysis of ...

With limited options in the treatment paradigm for refractory or unexplained chronic cough, P2X3 receptor antagonists have shown great promise in clinical trials. We were delighted to speak to Dr. Imran Satia (McMaster University, Hamilton, ON, Canada) to discuss ...